HLS Therapeutics Inc. (OTCMKTS:HLTRF) Stock Short Interest Report for September

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totaling 100 shares, a decrease of 93.5% from the September 15th total of 1,546 shares. Based on an average trading volume of 927 shares, the short-interest ratio is presently 0.1 days.

HLS Therapeutics Stock Performance

OTCMKTS:HLTRF remained flat at $2.75 during mid-day trading on Friday. HLS Therapeutics has a 12-month low of $2.64 and a 12-month high of $4.02. The firm has a 50 day moving average of $2.78 and a two-hundred day moving average of $3.03.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial raised HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating. According to MarketBeat, the company currently has an average rating of “Strong Buy”.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company focused on acquiring, developing and commercializing medicines in Canada and the United States. The company concentrates on products that address significant medical needs, with an emphasis on central nervous system and cardiovascular therapies.

HLS has commercialized branded prescription medicines and specialty products through partnerships, licensing arrangements and acquired product rights. Its portfolio has included Clozaril (clozapine), a treatment used in schizophrenia, as well as other therapies marketed through specialty-care and hospital channels.